Bin Zou
Founder & Chief Executive Officer Axcynsis
Bin Zou, Ph.D. is the Founder and Chief Executive Officer of Axcynsis Therapeutics, a Singapore-based biotechnology company pioneering next-generation antibody-drug conjugate (ADC) therapies for cancer. He also serves as Chairman of the company and brings deep experience in drug discovery and biotech leadership, including roles as Managing Director at Trinity Innovation Bioventure Singapore and CEO of Shanghai Blueray Biopharma. Previously, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease and has authored over 25 peer-reviewed publications. Additionally, he holds academic roles such as Adjunct Associate Professor at the National University of Singapore
Seminars
Tuesday 9th June 2026
Analyzing the Benefits of Using Cysteine Conjugation vs. Other Conjugation Technologies on Bispecific ADCs & Their Success Rate in Improving Stability of the Molecule
2:15 pm
- Evaluating cysteine conjugation vs. lysine, enzymatic and site-specific technologies, and their effect on DAR ratio and uniformity
- Assessing the impact of each conjugation technology on ADC stability
- Exploring how each conjugation technology affects clinical performance
